AUTHOR=Hu Chun-Hong , Shi Shenghao , Dong Wen , Xiao Lizhi , Zang Hongjing , Wu Fang 

TITLE=Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.799549

DOI=10.3389/fonc.2022.799549

ISSN=2234-943X

ABSTRACT=Primary pulmonary enteric adenocarcinoma (PEAC) is a rare invasive a denocarcinoma. Because it is very similar to metastatic colorectal adenocarcinoma (MCRC), most of the current international studies are on the differential diagnosis of them, while there are relatively few reports on the treatment of PEAC, and fewer reports on immunotherapy. This report describes a 61-year-old male patient with initial symptoms Pain for the ribs. Pathological biopsy showed malignant tumors of the right pleura, The test result of the 26 gene (NGS) method showed: KRAS gene mutation. PET-CT found no evidence of gastrointestinal malignancy. Due to multiple metastases, the patient cannot undergo radical surgery. The patient was given Paclitaxel combined with carboplatin regimen combined with sindilizumab immunotherapy, but after one cycle of treatment, the evaluation showed a tumor hyperprogressive state. We are still following up with the patient. Chemotherapy combined with immunotherapy may not be effective for patients with primary pulmonary enteric adenocarcinoma with positive driver genes.